Infographic: Impact of eteplirsen treatment in patients with Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a progressive muscle loss disorder that increases the reliance of patients on healthcare resources. Eteplirsen, a clinically-approved drug for DMD in the United States, has emerged as a beacon of hope for slowing DMD progression and enhancing patients’ quality of life. Our ‘Impact of Eteplirsen Treatment in Patients with Duchenne Muscular Dystrophy’ infographic spotlights the pivotal finding that Eteplirsen treatment significantly reduces the need for healthcare resources, from hospital visits to ventilator support.

This infographic was created with the help of Becaris Publishing Author Services, provided by Editage. If you’d like to receive professional assistance in summarizing your research into an eye-catching but scientifically accurate infographic such as this, please visit our Author Services by clicking here.

This infographic is a summary of an article originally published in the Journal of Comparative Effectiveness Research. The article is called ‘Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA’ and can be read here.

Infographic_Impact of Eteplirsen Treatment in Patients with Duchenne Muscular Dystrophy-compressed